![]() |
市場調查報告書
商品編碼
1454083
到 2030 年紅麴米市場預測:按產品類型、分銷管道、應用、最終用戶和地區進行的全球分析Red Yeast Rice Market Forecasts to 2030 - Global Analysis By Product Type (Powder, Extracts, Fermented Products, Capsule & Tablet and Other Product Types), Distribution Channel, Application, End User and By Geography |
根據Stratistics MRC預測,2023年全球紅麴米市場規模將達11億美元,預計2030年將達到24億美元,預測期內年複合成長率為12.4%。
紅麴米(RYR)是一種傳統的中國菜餚和藥物,由紅麴菌發酵米製成。莫納可林 K 含有一種天然化合物莫納可林,與降膽固醇藥物洛伐他汀相同。幾個世紀以來,RYR 一直被用於傳統中醫以促進心血管健康。其活性化合物被認為可以抑制膽固醇合成並降低低密度脂蛋白(「壞」)膽固醇水平。有些人使用 RYR 作為控制膽固醇水平的天然替代品。
人們對天然降膽固醇藥物的認知不斷增強
紅麴米越來越受歡迎。人們越來越意識到傳統降膽固醇藥物的副作用,促使人們轉向自然療法。消費者正在積極尋找像紅麴米產品可以提供一種自然的方法來控制膽固醇而不損害整體健康。因此,隨著人們意識到紅麴米在傳統醫學中的歷史用途與採用天然植物性健康解決方案的更廣泛趨勢之間的一致性,對紅麴米的需求激增。
安全問題和潛在的副作用
對紅麴米安全性的擔憂給市場蒙上了陰影。與嚴格監管的處方藥不同,紅麴米會導致肌肉疼痛、消化器官系統問題,並與其他藥物產生交互作用。這些潛在的副作用給消費者和醫療保健專業人員帶來了危險訊號。擔心意外後果的消費者可能會選擇成熟的藥物。由於缺乏長期資料以及與目前藥物的潛在交互作用,優先考慮患者安全的醫生也可能會猶豫是否推薦紅麴米。
心血管疾病盛行率增加
全球對心血管健康的關注日益增加,對有助於控制膽固醇(心血管健康的重要因素)的天然解決方案的需求也隨之增加。紅麴米含有莫納可林等可降低膽固醇水平的化合物,已被認為是預防心臟相關問題的潛在預防措施。越來越多的心血管疾病患者促使他們尋求積極主動的方法來管理他們的心臟健康,而紅麴米補充品的採用正在促進市場的成長。
與現有降膽固醇藥物的競爭
現有降膽固醇藥物的主導地位對紅麴米市場構成了主要障礙。這些處方藥擁有悠久的療效證明、廣泛的臨床研究和醫生的信任。這使得這些藥物成為許多醫療保健提供者的選擇,從而阻止紅麴米被納入主流膽固醇管理。此外,現有藥物可能包含在保險範圍內,與紅麴米的自付費用相比,對於某些患者來說,它們成為更具成本效益的選擇。
COVID-19 的影響
COVID-19大流行對紅麴米市場產生了兩個重要影響。首先,人們的注意力已經轉向眼前的健康問題。人們優先考慮 COVID-19 的治療和預防,而將高膽固醇等慢性健康問題放在次要位置。因此,對紅麴米等補充品的需求減少了。這使得製造商難以採購原料,經銷商也難以交付產品,阻礙了整體市場活動。儘管隨著人們更加關注預防性醫療保健,市場有望復甦,但疫情的影響可能會持續一段時間。
預計粉末細分市場在預測期內將是最大的
由於易於摻入各種食品和食品和飲料中,粉末行業預計將享受良好的成長,因為它擴展到傳統補充品之外的應用領域。這項創新滿足了消費者對便利性和可客製化消費的偏好,推動了需求和市場成長。此外,紅麴米通常保留其營養價值,並保持其降低膽固醇的特性,從而促進市場成長。
預計營養補充食品在預測期內年複合成長率最高
預計營養補充食品在預測期內將以最高的年複合成長率成長。這是因為它的降低膽固醇作用已被廣泛認可,並且是心血管保健補充品中廣受歡迎的成分。將紅麴米納入營養補充擴大了消費者的覆蓋範圍,並提供了一種方便、標準化的方式將紅麴米的健康益處融入個人的日常生活。將紅麴米與其他心臟健康成分混合的組合補充品的需求進一步增加了紅麴米市場的存在。
預計亞太地區將在預測期內佔據最大的市場佔有率,因為紅麴米因其獨特的風味和顏色而傳統上用於亞洲料理。紅麴米因其微妙的甜味而經常被使用,並賦予食品微紅色。此外,紅麴米因其潛在的健康益處而廣受歡迎,尤其是在控制膽固醇水平方面。一些研究表明,紅麴米中的莫納可林 K 可能有助於降低低密度脂蛋白膽固醇水平,從而推動市場成長。
紅麴米通常在北美作為營養補充出售和消費,預計它具有特別的降低膽固醇的作用,因此預計北美在預測期內的年複合成長率最高。消費者可以使用紅麴米補充品作為傳統他汀類藥物的天然替代品。此外,北美有多家公司生產和銷售紅麴米補充品,市場競爭包括產品品質、品牌聲譽和行銷策略等因素。
According to Stratistics MRC, the Global Red Yeast Rice Market is accounted for $1.1 billion in 2023 and is expected to reach $2.4 billion by 2030 growing at a CAGR of 12.4% during the forecast period. Red Yeast Rice (RYR) is a traditional Chinese culinary and medicinal product made by fermenting rice with the Monascus purpureus mold. It contains naturally occurring compounds known as monacolins, with monacolin K being identical to lovastatin, a cholesterol-lowering medication. RYR has been used for centuries in traditional Chinese medicine to promote cardiovascular health. Its active compounds are believed to inhibit cholesterol synthesis and lower LDL ("bad") cholesterol levels. Some people use RYR as a natural alternative for managing cholesterol levels.
Rising awareness of natural cholesterol-lowering solutions
As consumers become more health-conscious and seek alternatives to synthetic medications, red yeast rice, known for its potential to lower cholesterol levels, has gained popularity. The rising awareness of the adverse effects associated with conventional cholesterol-lowering drugs has driven individuals toward natural remedies. Consumers are actively seeking products like red yeast rice that offer a natural approach to managing cholesterol without compromising overall health. Thus, the demand for red yeast rice has surged as people recognize its historical use in traditional medicine and its alignment with the broader trend of embracing natural, plant-based solutions for health and wellness.
Safety concerns and potential side effects
Safety concerns surrounding red yeast rice cast a shadow over the market. Unlike strictly regulated prescription drugs, red yeast rice can cause muscle aches, digestive issues, and interact with other medications. These potential side effects raise red flags for both consumers and healthcare professionals. Consumers wary of unintended consequences may opt for established medications. Further doctors, prioritizing patient safety, might hesitate to recommend red yeast rice due to the lack of long-term data and potential interactions with current medications.
Growing prevalence of cardiovascular diseases
Cardiovascular health concerns escalate globally; there is an increased demand for natural solutions that can contribute to cholesterol management, a key factor in cardiovascular health. Red yeast rice, containing compounds like monacolins, which may help lower cholesterol levels, has gained attention as a potential preventive measure against heart-related issues. The rise in CVD cases has prompted individuals to seek proactive approaches to manage heart health, driving the adoption of red yeast rice supplements contributing to the market growth.
Competition from established cholesterol-lowering drugs
The dominance of established cholesterol-lowering medications throws a significant hurdle at the red yeast rice market. These prescription drugs boast a long history of proven effectiveness, extensive clinical research, and the trust of doctors. This makes them the go-to option for many healthcare providers, hindering red yeast rice's integration into mainstream cholesterol management. Furthermore, established drugs may be covered by insurance, making them a more cost-effective choice for some patients compared to out-of-pocket expenses for red yeast rice.
Covid-19 Impact
The COVID-19 pandemic impacted the red yeast rice market in two key ways. Firstly, the focus shifted towards immediate health concerns. People prioritized treating and preventing COVID-1chronic health conditions like high cholesterol took a backseat. This led to a decline in demand for supplements like red yeast rice. This made it difficult for manufacturers to source ingredients and distributors to deliver the product, hindering overall market activity. While the market is expected to recover as people resume focusing on preventative healthcare, the pandemic's effects are likely to be felt for some time.
The powder segment is expected to be the largest during the forecast period
The powder segment is estimated to have a lucrative growth, owing to ease of incorporation into various food and beverage products, expanding its usage beyond traditional supplements. This innovation caters to consumer preferences for convenient and customizable consumption, driving demand and market growth. Additionally, powdered Red Yeast Rice often retains its nutritional benefits, maintaining its cholesterol-lowering properties encourage the market growth.
The dietary supplements segment is expected to have the highest CAGR during the forecast period
The dietary supplements segment is anticipated to witness the highest CAGR growth during the forecast period, due to widely recognized for its potential cholesterol-lowering benefits, it has become a sought-after ingredient in cardiovascular health supplements. The incorporation of Red Yeast Rice into dietary supplements has expanded its consumer reach, offering individuals a convenient and standardized way to incorporate its health benefits into their daily routines. The demand for combination supplements, blending Red Yeast Rice with other heart-healthy ingredients, has further amplified its market presence.
Asia Pacific is projected to hold the largest market share during the forecast period because red yeast rice has been traditionally used in Asian cuisines for its distinctive flavor and color. It is often used to impart a reddish hue to food, as well as for its subtle sweet taste. Moreover, red yeast rice has gained popularity for its potential health benefits, particularly in managing cholesterol levels. Some studies suggest that the monacolin K in red yeast rice may help a lower LDL cholesterol level which boosts the market growth.
North America is projected to have the highest CAGR over the forecast period, as red yeast rice is often marketed and consumed in North America as a dietary supplement, particularly for its potential cholesterol-lowering properties. Consumers may use red yeast rice supplements as a natural alternative to traditional statin medications. Additionally, various companies in North America may produce and distribute red yeast rice supplements and competition in the market can involve factors such as product quality, brand reputation, and marketing strategies.
Key players in the market
Some of the key players in the Red Yeast Rice Market include Shanghai Fengyi Biotechnology Co., Ltd, Nutraceuticals International Group, Golden Grain Group Limited, Zhejiang Sanhe Bio-Tech Co., Ltd., Nanjing Zelang Medical Technology Co., Ltd., Wuhan Jiacheng Biotechnology Co., Ltd, Fermentek Biotechnology, Hebei Food Additive Co., Ltd., CSPC Pharmaceutical Group Limited, Alesco S.r.L., Amazing Nutrition, Giellepi SpA, Sylvan Wellness, PLAMED Green Science Group, NOW Health Group, Purelife Bioscience Co Ltd, Natural Plus and Swanson
In January 2024, NOW Sports Named Official Sports Nutrition Partner of the Brooks Beasts Track Club. The strategic alignment comes as Brooks professional athletes look to compete on the world's biggest stage at this summer's 2024 Paris Olympics
In January 2024, NOW Partners with Top Wellness Experts to Launch You're Enough NOW Campaign. Peloton instructor emma lovewell, Celebrity Health Coach Kelly LeVeque, and Functional Medicine Practitioner Dr. Will Cole Will Inspire People to Feel Fulfilled, Nourished and Strong
In July 2023, Plamed launched a speech and participated the exhibition at Ringier PCT 2023. Many big names from domestic and foreign beauty and personal care brands, raw material supplier, OEM companies, scientific research institutes, and industry associations gathered in large numbers.